Journal article icon

Journal article

Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection

Abstract:

An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection, would significantly reduce the global burden of disease associated with chronic HCV infection. A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime/boost regimen induced multi-s...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.3390/vaccines4030027

Authors


More by this author
Department:
Oxford, MSD, NDM, NDM Experimental Medicine
More by this author
Department:
Oxford, MSD, NDM, NDM Experimental Medicine
More by this author
Department:
Oxford, MSD, NDM, NDM Experimental Medicine
More by this author
Department:
Oxford, MSD, NDM, NDM Experimental Medicine
Expand authors...
More from this funder
Grant:
Developmental Clinical Studies award (G0701694)
More from this funder
Grant:
(Framework VI; HEPACIVAC)
More from this funder
Funding agency for:
Swadling, L
More from this funder
Funding agency for:
Kelly, C
Expand funders...
Publisher:
MDPI Publisher's website
Journal:
Vaccines Journal website
Issue:
3
Publication date:
2016-08-02
DOI:
ISSN:
2076-393X
Pubs id:
pubs:634778
URN:
uri:b08d2ca3-5452-4a94-a1a0-227034acf805
UUID:
b08d2ca3-5452-4a94-a1a0-227034acf805
Local pid:
pubs:634778

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP